NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Clinical trials for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) explained in plain language.
Never miss a new study
Get alerted when new NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) trials appear
Sign up with your email to follow new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New eye drug faricimab tested for blinding disease
Disease control Not yet recruitingThis study will test the drug faricimab, given as eye injections, in 50 people with wet age-related macular degeneration (nAMD). The goal is to see if it improves vision and eye health. Participants will receive 4 initial doses, then more as needed. The study is observational, me…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New eye drug aims to match leading treatment for blinding disease
Disease control Not yet recruitingThis phase 3 trial tests whether a new drug, QL1207H, works as well as the standard treatment Eylea for wet age-related macular degeneration, a leading cause of vision loss. About 356 adults aged 50 and older with active disease will receive injections every 4 weeks for 3 doses, …
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: PHASE3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New eye drug GB10 enters early human testing for wet AMD
Disease control Not yet recruitingThis early-stage trial tests a new drug called GB10, given as an eye injection, for people with wet age-related macular degeneration (AMD). The study will include 48 participants and aims to check safety and find the right dose. It is not yet recruiting and is too early to know i…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: PHASE1 • Sponsor: Shenzhen Kexing Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Could a cotton swab replace the metal speculum for eye injections?
Symptom relief Not yet recruitingThis study tests if using a cotton-tipped applicator to hold the eyelid open during eye injections is less painful and faster than the standard metal speculum. About 120 adults with certain eye conditions will take part. The goal is to improve comfort and satisfaction without com…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: NA • Sponsor: Jakkrit Juhong • Aim: Symptom relief
Last updated Jun 27, 2026 11:02 UTC